Prime Editing Unlocks a Universal Strategy for Restoring Lost Proteins
November 22, 2025
Brand Name :
Ferromyn
Synonyms :
Iron succinate
Class :
Blood modifier agent, Anti-anemic, Hematinic, Supplement (iron)
Dosage Forms & StrengthsÂ
TabletÂ
1.5 mgÂ
Indicated for the treatment of iron deficiency anemia
The usual dose recommended via oral administration is 1.5 to 2.0 mg/kg every 8 hours in a day
Duration: 6–8 weeks following the restoration to normal of the haemoglobin level and red cell indices
Note:Correction of haemoglobin level and replenishment of bodily iron reserves are the two main objectives of iron deficiency therapy
Dose Adjustments
N/A
Limited data is availableÂ
Refer to the adult dosingÂ
It may enhance the risk of adverse effects when combined with Haemopoetic agents
ferrous succinate has the potential to impair the absorption of alendronic acid, which could compromise its efficacy by lowering serum levels
almasilate may inhibit the absorption of ferrous succinate, resulting in a drop in serum levels and possible reduction in efficacy
aluminium phosphate has the ability to inhibit the absorption of ferrous succinate, which can lower serum levels and possibly affect efficacy
aluminium hydroxide may impede the absorption of ferrous succinate, resulting in a drop in serum levels and a reduction in efficacy
asenapine has the ability to reduce the absorption of ferrous succinate, which can lower serum levels and perhaps compromise efficacy
ferrous succinate has the potential to impair lipoic acid absorption, which could compromise efficacy by lowering serum levels
lower serum concentrations and perhaps compromised efficacy of lomefloxacin can result from decreased absorption caused by ferrous succinate
lymecycline has the potential to diminish serum levels and compromise efficacy by decreasing the absorption of ferrous succinate
a decrease in the absorption of trovafloxacin due to ferrous succinate may lower serum concentrations and perhaps jeopardise efficacy
ferrous succinate has the potential to impair zoledronic acid absorption, which could compromise efficacy by lowering serum levels
a decrease in the efficacy of ferric pyrophosphate can be seen when administered with ferrous succinate
Actions and Spectrum:Â
Actions:Â
An additional supply of elemental iron is ferrous succinate, which is necessary for red blood cell hemoglobin production. Iron makes up a considerable portion of hemoglobin, from where the oxygen reaches every tissue in the body via the lungs. Enough iron must be present for the body to produce functioning hemoglobin.Â
Spectrum:Â
Ferrous succinate is a form of iron supplement, and its primary role is to provide a source of elemental iron for the body, especially when dietary intake is insufficient or when there is a need for increased iron levels, such as in the case of iron deficiency anemia.Â
Frequency not definedÂ
Metallic tasteÂ
ConstipationÂ
NauseaÂ
Abdominal crampsÂ
DiarrheaÂ
Black Box Warning:Â
 N/AÂ
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy consideration:Â Â
No data is available regarding the administration of the drug during pregnancy.Â
Breastfeeding warnings:Â Â
No data is available regarding the excretion of drug in breast milk.Â
Pregnancy category:Â
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: No data is available for the drug under this category.Â
Pharmacology:Â
The synthesis of haemoglobin requires iron. A microcytic, hypochromic anaemia can result from low haemoglobin production caused by an iron deficit.Â
Pharmacodynamics:Â
Iron deficiency anaemia is primarily prevented and treated with additional iron. There are potential immune-boosting, anticarcinogenic, and cognitive-enhancing effects of iron.Â
Pharmacokinetics:Â
AbsorptionÂ
The effectiveness of absorption relies on factors such as the salt form, administered quantity, dosing schedule, and existing iron reserves. Individuals with adequate iron stores typically absorb 10% to 35% of an iron dose, while those experiencing iron deficiency may absorb as much as 95% of the administered iron dose.Â
DistributionÂ
Absorbable iron is carried by the blood and linked to transferrin.Â
MetabolismÂ
In the body, iron undergoes very little metabolism.Â
Elimination and ExcretionÂ
The body doesn’t have a controlled system in place to actively eliminate extra iron. The body stores iron mostly in tissues, especially the liver.Â
Iron’s half-life varies based on bodily iron status and individual physiology, among other things.Â
Administration:Â
The administration of ferrous succinate, like other iron supplements, typically involves taking the medication orally. To improve absorption, iron supplements are often taken empty-handed, ideally an hour before or two after meals. However, if the iron causes stomach upset, it may be taken with food.
Vitamin C can also enhance iron absorption, so taking the supplement with a source of vitamin C may be recommended. It’s important to take ferrous succinate consistently as prescribed by the healthcare provider. Missing doses or inconsistent use may impact the effectiveness of the treatment.Â
Patient information leafletÂ
Generic Name: ferrous succinateÂ
Pronounced: Fer-uss SUCK-sin-ateÂ
Why do we use ferrous succinate?Â
Ferrous succinate serves as an iron supplement utilized in preventing and treating iron deficiency anemia. This condition arises from an insufficient iron supply in the body, resulting in a decline in hemoglobin production and, consequently, a diminished ability of the blood to transport oxygen.Â